Nonserious related adverse events (AEs) reported during the study period, excluding decreased CD4+ T-cell counts
| . | No. patients (no. events) . | ||
|---|---|---|---|
| Grade 1 . | Grade 2 . | Grade 3 . | |
| Skin and subcutaneous tissue disorders | |||
| Eczema and dermatitis | 4 (4) | 3 (3) | 2 (2) |
| Urticaria | 1 (1) | 2 (2) | 0 (0) |
| Pruritus | 2 (2) | 3 (3) | 2 (2) |
| Other skin and subcutaneous tissue disorders | 6 (6) | 2 (2) | 0 (0) |
| General disorders and administration-site conditions | |||
| Fatigue | 9 (11) | 0 (0) | 0 (0) |
| Flulike symptoms | 4 (8) | 3 (3) | 1 (1) |
| Other general disorders and administration-site conditions | 13 (25) | 4 (4) | 0 (0) |
| Infections and infestations | |||
| Skin-related infections | 3 (3) | 2 (3) | 0 (0) |
| Upper respiratory tract infections | 1 (1) | 0 (0) | 0 (0) |
| Pneumonia | 0 (0) | 1 (1) | 0 (0) |
| Oral candidiasis | 0 (0) | 1 (1) | 0 (0) |
| Other system organ classes | |||
| Muscle fiber rupture | 0 (0) | 0 (0) | 1 (1) |
| Other | 20 (48) | 10 (13) | 0 (0) |
| . | No. patients (no. events) . | ||
|---|---|---|---|
| Grade 1 . | Grade 2 . | Grade 3 . | |
| Skin and subcutaneous tissue disorders | |||
| Eczema and dermatitis | 4 (4) | 3 (3) | 2 (2) |
| Urticaria | 1 (1) | 2 (2) | 0 (0) |
| Pruritus | 2 (2) | 3 (3) | 2 (2) |
| Other skin and subcutaneous tissue disorders | 6 (6) | 2 (2) | 0 (0) |
| General disorders and administration-site conditions | |||
| Fatigue | 9 (11) | 0 (0) | 0 (0) |
| Flulike symptoms | 4 (8) | 3 (3) | 1 (1) |
| Other general disorders and administration-site conditions | 13 (25) | 4 (4) | 0 (0) |
| Infections and infestations | |||
| Skin-related infections | 3 (3) | 2 (3) | 0 (0) |
| Upper respiratory tract infections | 1 (1) | 0 (0) | 0 (0) |
| Pneumonia | 0 (0) | 1 (1) | 0 (0) |
| Oral candidiasis | 0 (0) | 1 (1) | 0 (0) |
| Other system organ classes | |||
| Muscle fiber rupture | 0 (0) | 0 (0) | 1 (1) |
| Other | 20 (48) | 10 (13) | 0 (0) |